| abstract |
A method of inhibiting, reducing, and/or treating pathological apoptosis and/or protein aggregation in a subject includes administering to the subject an amount of a therapeutic polypeptide effective to inhibit, reduce, and/or treat the pathological apoptosis and/or protein aggregation. The therapeutic polypeptide including at least one of acetylated aA-crystallin, acetylated aB-crystallin, acetylated fragments thereof having molecular chaperone activity, and/or polypeptide mimetics thereof that can inhibit pathological protein aggregation and/or pathological apoptosis. |